Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report), retaining the price target of $45.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sam Slutsky’s rating is based on several compelling factors. The Phase 2b study of obefazimod in ulcerative colitis showed similar efficacy across different doses, suggesting that the 25 mg, 50 mg, and 100 mg doses perform comparably. This consistency is supported by pharmacodynamic data, indicating that the 25 mg dose might be at the upper end of the dose-response curve. The ongoing Phase 3 program is evaluating the 25 mg and 50 mg doses, while a Phase 2b study in Crohn’s disease is exploring a 12.5 mg dose to further understand the dose-response relationship.
Additionally, the 50 mg dose demonstrated durable and promising efficacy in long-term use, as evidenced by the open-label extension study. The initial Phase 2a study with a 50 mg dose also showed encouraging results, with a significant clinical remission rate compared to placebo. These findings collectively reinforce the potential of obefazimod as an effective treatment option, justifying the Buy rating for Abivax SA Sponsored ADR.
In another report released on June 16, Guggenheim also reiterated a Buy rating on the stock with a $50.00 price target.